Exercise of Options, Issue of Equity & TVR

Instem plc

02 June 2023

 

Instem plc

 ("Instem", the "Group" or the "Company")

Exercise of Options, Issue of Equity & Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, confirms that it has issued, conditional on admission, 20,000 ordinary shares ("New Ordinary Shares"), pursuant to an exercise of share options by an employee of the Company on 1 June 2023.

Issue of Equity and Admission

Application will be made to the London Stock Exchange for the admission of the 20,000 New Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00 a.m. on 07 June 2023.  

Total voting rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,889,433 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,889,433.

The figure of 22,889,433 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact: Instem plc Via Walbrook Phil Reason, CEO Nigel Goldsmith, CFO Singer Capital Markets (Nominated Adviser & Broker) [phone] Peter Steel Alex Bond Stifel Nicolaus Europe Limited (Joint Broker) [phone] Ben Maddison Alex Price Richard Short Walbrook Financial PR [phone] Tom Cooper [e-mail] Nick Rome Joe Walker

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END